Advanced Filters
noise

Fairfax, Virginia Clinical Trials

A listing of Fairfax, Virginia clinical trials actively recruiting patient volunteers.

Found 301 clinical trials
E Epp Goodwin

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

This is a Phase 1 and Phase 2 study to determine the safety profile, RDR and/or MTD, DLT, PK/PD, and preliminary antitumor activity of INV-9956 in adult patients with advanced mCRPC.

18 years of age Male Phase 1/2
J Jamie White

A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

18 years of age All Phase 1
S Sevinj, Sr. Clinical Research Coordinator

A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor (EGFRi) therapy. The primary goal of the study is to determine safety and tolerability of ATR04-484, and the secondary goal of the study is to assess …

18 years of age All Phase 1/2
N Navin K Kapur, MD

Cardiogenic Shock Working Group Registry

The Cardiogenic Shock Working Group is a multicenter registry where we collect de-identified clinical variables from the medical records and follow-up phone calls of shock patients from multiple institutions and centralize this data to a single registry for analysis of clinical outcomes.

18 years of age All Phase N/A
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Genome Transplant Dynamics

Background Some people with advanced heart and lung disease have heart and lung transplants. But the organs are often rejected. When this happens, the organ recipients must have repeated biopsies. These are invasive and expensive. Researchers want to see if a blood test can predict rejection and take the place …

18 - 80 years of age All Phase N/A

Inova Cardiogenic Shock Registry (INOVA SHOCK)

To collect retrospective clinical outcomes related to acute decompensated heart failure cardiogenic shock, acute myocardial infarction cardiogenic shock and compare current versus historical survival rates. To collect Inova Heart and Vascular Institute (IHVI) site specific outcomes before and after initiation of the Cardiogenic Shock team on January 1, 2017. To …

18 - 85 years of age All Phase N/A

Medtronic Cardiac Surgery PMCF Registry

This registry is being conducted to support ongoing post-market surveillance activities.

years of age All Phase N/A
B Brooke McDaniel

Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

This collaborative screening protocol, developed by the Lung Cancer Mutation Consortium (LCMC) and supported by the Thoracic Surgery Oncology Group (TSOG), is designed to determine the feasibility of comprehensive molecular profiling to detect actionable oncogenic drivers in patients with suspected early stage lung cancers scheduled to undergo biopsies to establish …

years of age All Phase N/A

Product Surveillance Registry

The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge …

years of age All Phase N/A
A Audra Wiser

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases …

21 years of age All Phase N/A

Simplify language using AI